

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 May 2025 (15.05.2025)



(10) International Publication Number
WO 2025/101484 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/054513

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
05 November 2024 (05.11.2024)

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(30) Priority Data:
63/596,588 06 November 2023 (06.11.2023) US
63/694,763 13 September 2024 (13.09.2024) US
63/699,700 26 September 2024 (26.09.2024) US

(71) Applicant: **IOVANCE BIOTHERAPEUTICS, INC.**
[US/US]; 825 Industrial Road, Suite 400, San Carlos, CA
94070 (US).

(72) Inventors: **VOGT, Frederick, G.**; 2120 Hemlock Road,
West Norriton, PA 19401 (US). **VON FINCKENSTEIN,
Friedrich, Graf, Finck**; 19 Dover Court, San Carlos, CA
94070 (US).

(74) Agent: **MACDOUGALL, Christina, A.** et al.; Morgan,
Lewis & Bockius LLP, One Market, Spear Street Tower,
San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATMENT OF ENDOMETRIAL CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES

(57) Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of endometrial cancer. In an embodiment, the invention provides methods and compositions for the treatment of uterine cancer using tumor infiltrating lymphocyte therapies. In an embodiment, the invention provides methods and compositions for the treatment of endometrial cancer using tumor infiltrating lymphocyte therapies, wherein the endometrial cancer is resected and processed to prepare tumor infiltrating lymphocytes.



WO 2025/101484 A1